YOU ARE ABOUT TO EXIT A GLOBAL HEMANEXT ONE PRODUCT WEBSITE FOR THE US HEMANEXT CORPORATE WEBSITE

Please be aware that the website you have requested is intended for the residents of the United States. The Hemanext One® System has not been cleared, approved, or otherwise authorized by the US Food & Drug Administration for commercial distribution in the United States.
WITH DO YOU WISH TO CONTINUE AND EXIT THIS WEBSITE?
Yes No
Hemanext.com info@hemanext.com
Hemanext One
  • HCP
    • Hemanext ONE
  • IFU
  • News
  • Contact
Select Page

Hemanext Partners with Sickle Cell 101 to Sponsor Sickle Cell Education

Hemanext, News, SCD

Sickle Cell Disease (SCD) Affects Over 20M Worldwide, including 100K Americans1,2 LEXINGTON, MA and SAN FRANCISCO, CA – Jul 28, 2021 – Hemanext Inc. a privately held, US-based medical technology company dedicated to improving the quality, safety, efficacy, and cost of...

Hemanext® Inc. Receives CE Mark Certification for Innovative Red Blood Cell (RBC) Processing & Storage System

News, Red Blood Cell

Hemanext® Inc. Receives CE Mark Certification for Innovative Red Blood Cell (RBC) Processing & Storage System Company to launch Hemanext ONE® RBC Processing and Storage System in select European markets in 2021, with wider distribution in Europe and the Americas...
Next Entries »

Recent Posts

  • Hemanext Announces Close of Series B Equity Funding Round
  • European Patients Have Begun Receiving Transfusions with Hemanext ONE® RBC Processing and Storage System
  • Hemanext Launches European Sales of Hemanext One® System in Italy and The Nordics
  • Hemanext Announces Publication of Hypoxic Blood Storage Study in Blood Advances
  • Hemanext to Begin Rollout of Hemanext ONE® RBC Processing and Storage System in Europe
Information contained herein for distribution outside the United States only. The site may contain information on products or uses of those products that are not cleared, approved, or otherwise authorized in all countries or regions. The Hemanext ONE® System has not been cleared, approved, or otherwise authorized by the US Food & Drug Administration for commercial distribution in the United States.

CAUTION: The novel Hemanext ONE Red Blood Cell (RBC) Processing and Storage System is a prescription medical device designed to limit oxygen and carbon dioxide levels in the storage environment to be used by or under the direction of a physician. It is CE-marked as a blood container set for the processing and storage of CPD/PAGGSM Red Blood Cells, Leukocytes Reduced (LRRBC) that have been prepared and processed with the HEMANEXT ONE system within 24-hours of collection. The HEMANEXT ONE system limits the O2 and CO2 levels in the storage environment. Red Blood Cells Leukocytes Reduced, O2/CO2 Reduced may be stored for up to 42 days at 1-6°C. HEMANEXT ONE is used for volumes no greater than 350 ml of LR. Prior to use, for more detailed information reference the Instructions for Use regarding the Device Description, Indications, Contraindications, Warnings, Precautions, and Adverse Events.

INSTRUCTIONS FOR USE | MEDICAL INFORMATION | CONTACT US | TERMS OF USE | PRIVACY & COOKIES POLICY | HEMANEXT.COM

© 2021 Hemanext, Inc. All Rights Reserved. This website and the information contained herein is for informational purposes and only for selected audiences, like healthcare professionals. It is not directed to patients.

99 Hayden Avenue, Building B, Suite 620, Lexington, MA 02421 USA [MKTG-0065 A00]